Fifty-five adults with obesity and MASLD followed an 8-week very-low-calorie ketogenic diet (VLCKD) and were assessed before and after. Transient elastography showed significant drops in controlled attenuation parameter (steatosis, p<0.0001) and liver stiffness (p=0.0005), alongside smaller waist circumference and fat mass (both p<0.0001). Leptin fell, while sex hormone-binding globulin (SHBG), a marker linked to better hepatic and metabolic health, rose significantly (p<0.0001).
The direction fits what we already know: substantial short-term weight loss, by almost any route, shrinks liver fat, and a 7-10% loss is the benchmark associated with improved steatohepatitis and fibrosis. The real question is whether VLCKD offers anything beyond rapid calorie restriction, and this design cannot answer it. There is no control arm, no MedDiet comparison, and no adjustment for the weight loss itself, so the liver gains may simply track the kilograms lost. Eight weeks also says nothing about durability; ketogenic protocols are notorious for regain once carbohydrates return, and liver fat tends to follow. FibroScan stiffness can also improve with reduced hepatic fat and inflammation without true fibrosis regression, and no biopsy or hard clinical outcomes were measured.
The SHBG and leptin shifts are the more interesting signal, hinting at improved adipose-liver crosstalk, but they remain associative. Editorially, this is confirmatory and hypothesis-generating. For adults with MASLD who struggle to sustain a Mediterranean pattern, VLCKD looks like a plausible short-term tool, best used under medical supervision with a planned transition to a sustainable diet, pending randomized head-to-head trials.